Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations

Lotte Nygård, Lise B Ahlborn, Gitte F Persson, Dineika Chandrananda, Jonathan W Langer, Barbara M Fischer, Seppo W Langer, Miglė Gabrielaite, Andreas Kjær, Nitzan Rosenfeld, Florent Mouliere, Olga Østrup, Ivan R Vogelius, Søren M Bentzen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: The overall aim was to investigate the change over time in circulating cell free DNA (cfDNA) in patients with locally advanced non-small cell lung cancer (NSCLC) undergoing concurrent chemo-radiotherapy. Furthermore, to assess the possibility of detecting circulating cell free tumor DNA (ctDNA) using shallow whole genome sequencing (sWGS) and size selection.

METHODS: Ten patients were included in a two-phase study. The first four patients had blood samples taken prior to a radiation therapy (RT) dose fraction and at 30 minutes, 1 hour and 2 hours after RT to estimate the short-term dynamics of cfDNA concentration after irradiation. The remaining six patients had one blood sample taken on six treatment days 30 minutes post treatment to measure cfDNA levels. Presence of ctDNA as indicated by chromosomal aberrations was investigated using sWGS. The sensitivity of this method was further enhanced using in silico size selection.

RESULTS: cfDNA concentration from baseline to 120 min after therapy was stable within 95% tolerance limits of +/- 2 ng/ml cfDNA. Changes in cfDNA were observed during therapy with an apparent qualitative difference between adenocarcinoma (average increase of 0.69 ng/ml) and squamous cell carcinoma (average increase of 4.0 ng/ml). Tumor shrinkage on daily cone beam computer tomography scans during radiotherapy did not correlate with changes in concentration of cfDNA.

CONCLUSION: Concentrations of cfDNA remain stable during the first 2 hours after an RT fraction. However, based on the sWGS profiles, ctDNA represented only a minor fraction of cfDNA in this group of patients. The detection sensitivity of genomic alterations in ctDNA strongly increases by applying size selection.

Original languageEnglish
Article numbere0231884
Pages (from-to)e0231884
JournalPLoS ONE
Volume15
Issue number4
DOIs
Publication statusPublished - 28 Apr 2020

Cite this

Nygård, L., Ahlborn, L. B., Persson, G. F., Chandrananda, D., Langer, J. W., Fischer, B. M., ... Bentzen, S. M. (2020). Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients - initial observations. PLoS ONE, 15(4), e0231884. [e0231884]. https://doi.org/10.1371/journal.pone.0231884